Search

… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … and we are pleased to partner with them, aiming to bring a therapy to patients in an area of unmet need for a …

… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a … Title:  Phase 1b/2 interim results of QR-421a RNA therapy in retinitis pigmentosa due to mutations in the USH2A …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: …

… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … amaurosis 10 (LCA10) and the investigational RNA therapy for LCA10, sepofarsen experience to date. The call …

… in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that …

… supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform and continued advancement of … company dedicated to changing lives through transformative RNA therapies, and Laboratoires Théa, the leading independent … Sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …

… expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal … to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today …

… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to changing lives through the creation of transformative RNA therapies, today provided an update on its ophthalmology … s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …